ASCO 2020: Updates in renal cancer
ASCO 2020: Updates in renal cancer
Highlights from ASCO 2020
PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway
Timing of response to venetoclax combination treatment in older patients with acute myeloid leukaemia
ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer
Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma
KRd vs VRd for initial therapy of newly diagnosed multiple myeloma
Association of BRCA alterations with response to PARP inhibitors in metastatic castration-resistant prostate cancer
LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docetaxel
The paediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups
Better genetic diagnostics in Ugandan breast cancer patients
Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associated breast cancer